T1	Participants 108 201	the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin
T2	Participants 205 326	A total of 465 patients with primary and multiple or recurrent, stages Ta and T1 superficial bladder cancer were included
T3	Participants 486 527	after transurethral resection of tumor(s)
